Navigation Links
Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy

ll clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. The Company is conducting clinical trials with hA20 in patients with non-Hodgkin's lymphoma, epratuzumab as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and hCD74 as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock and Lock (DNL) methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. For additional information on us, please visit our web site at http://www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward- looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/25/2014)...  CVS Caremark Corporation (NYSE: CVS ) ... 5, 2014, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call ... of the CVS Caremark website for all interested parties.  ... webcast will be archived and available on the web ...
(Date:7/25/2014)... 25, 2014  Solanbridge Group Inc (OTC: SLNX) is ... interest in Buzznbrewz.com and the Letter of Intent issued ... fully executed Purchase Agreement. Charles R. ... proud to have Mr. David Pecoraro and ... in the private sector and developed a tremendous network ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
Breaking Medicine Technology:Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Actavis Group, the international generic pharmaceuticals company, ... US Food & Drug Administration to market Losartan Potassium ... 25 mg, 50 mg and 100 mg strength.  Losartan ... Iceland. Losartan Potassium Tablets, USP had US ...
... 12 WPI Holdings d/b/a Woodbury Health Products ("Woodbury"), ... announced today that it has completed the acquisition of ... Wilmington, North Carolina and founded in 1993, WMS is ... focused on urological catheters and sterile kits.  With a ...
Cached Medicine Technology:Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S. 2WPI Holdings Acquires Wilmington Medical Supply Inc. 2
(Date:7/27/2014)... (PRWEB) July 27, 2014 1-Butene is ... has good solvent properties. 1–Butene can be manufactured either ... from the reaction of ethylene. Linear alpha olefin (alkene) ... to manufacture a number of important chemicals such as ... and so on. , The 1-Butene market is extremely ...
(Date:7/27/2014)... Metachromatic leukodystrophy (MLD, also called Arylsulfatase ... is commonly listed in the family of leukodystrophies ... affects the metabolism of sphingolipids. Leukodystrophies affect the ... which acts as an insulator around nerve fibers ... involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most ...
(Date:7/27/2014)... -- Couples aren,t more likely to get divorced if ... research finds. The study only looks at trends ... a direct role in affecting whether couples stay together ... against fears that women,s growing educational advantage over men ... lead author of the study, said in an American ...
(Date:7/27/2014)... 2014 Ticket Down is a ... tickets in Miami, FL at the Sun Life Stadium ... is officially underway. In the opening game, Olympiacos from Superleague ... out to an early lead in their group. Six other ... this mini-tournament including Manchester City, Manchester United, AS Roma, Liverpool ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... a special promotion for fall meetings booked at the ... at this Downtown Denver hotel, just steps away from ... Denver’s central business district, and over 100 restaurants and ... their fall 2014 meetings at the HGI Denver will ...
Breaking Medicine News(10 mins):Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 3Health News:Stonebridge Companies’ Hilton Garden Inn Denver Downtown Announces Fall Meeting Promotion 2
... explain why C-section babies seem more likely to develop ... (HealthDay News) -- Babies who are born vaginally pick ... cesarean section, potentially affecting how their immune systems develop, ... provide more insight into why babies born through cesarean ...
... the polycystic ovary syndrome (PCOS), the most common hormone imbalance ... exposure to the chemical bisphenol A (BPA), found in many ... will be presented Sunday at The Endocrine Society,s 92nd Annual ... a known hormone disrupter, is elevated and associated with higher ...
... ... and revenues. In this Social Media Zuberance webinar we will show you how to avoid becoming ... ... (Founder and CEO of Zuberance) for a free interactive webinar at 11 AM PDT/2 ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... to Doctors, Physicians and Health Care Providers will monetize their time and streamline their patient ... the next sixty days. , ... (PRWEB) June 21, 2010 -- DocGreet.com is so sure that the services available to ...
... mental disorder affecting one in 100 people worldwide. Most cases ... and hallucinations as a teenager or adult. By that time, ... be difficult to treat. In a paper published recently ... at the University of North Carolina at Chapel Hill and ...
Cached Medicine News:Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:Women with polycystic ovary syndrome have higher BPA blood levels 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Brain signs of schizophrenia found in babies 2
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
... contributes to successful outcomes for your ... and technique, the materials you choose ... patients' outcomes, both short-term and long-term. ... Polyethylene. MARATHON Polyethylene is the first ...
Medicine Products: